For research use only. Not for therapeutic Use.
<p>
Tenalisib(cas# 1639417-53-0), also known as RP6530, is a potent and selective dual PI3Kδ/γ inhibitor that inhibited growth of B-cell lymphoma cell lines with a concomitant reduction in the downstream biomarker, pAKT. Additionally, the compound showed cytotoxicity in a panel of lymphoma primary cells. Findings provide a rationale for future clinical trials in B-cell malignancies.
</p>
<p>
It has already completed a Phase I trial for Haematological malignancies.
</p>
| Catalog Number | I009750 |
| CAS Number | 1639417-53-0 |
| Synonyms | RP6530; RP6530; RP 6530; Tenalisib.;(S)-2-(1-((7H-purin-6-yl)amino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one |
| Molecular Formula | C23H18FN5O2 |
| Purity | ≥95% |
| Target | PI3K |
| Solubility | Soluble in DMSO, not in water |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| Related CAS | 1693773-94-2 |
| SMILES | O=C1C(C2=CC=CC(F)=C2)=C([C@@H](NC3=C4NC=NC4=NC=N3)CC)OC5=C1C=CC=C5 |
| Reference | 1. Swaroop Vakkalanka, Srikant Viswanadha, Eugenio Gaudio, Emanuele Zucca, Francesco Bertoni, Elena Bernasconi, Davide Rossi, Anastasios Stathis, Dual PI3Kδ/γ Inhibition By RP6530 Induces Apoptosis and Cytotoxicity In B-Lymphoma Cells. Blood October 21, 2013 vol. 122 no. 21 4411.<br /> |
